Medical Device

Medtronic plc a global leader in healthcare technology, today announced Austin L. Chiang M.D., M.P.H., assistant professor of medicine at Sidney Kimmel Medical College, chief medical social media officer of Jefferson Health and director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, has joined Medtronic as Chief Medical Officer of the Gastrointestinal business at Medtronic. In this ...

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced Austin L. Chiang M.D., M.P.H., assistant professor of medicine at Sidney Kimmel Medical College, chief medical social media officer of Jefferson Health and director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, has joined Medtronic as Chief Medical Officer (CMO) of the Gastrointestinal (GI) business at Medtronic.

In this role, Dr. Chiang will provide medical expertise and strategic guidance on evidence development, clinical communications and publications, and training and support needs. Additionally, he will provide oversight to ensure patient safety throughout product lifecycle, including the product development processes, risk management, clinical trials, and safety surveillance. Dr. Chiang is one of the few triple board-certified advanced endoscopy-trained physicians in the world. His certifications include Internal Medicine and Gastroenterology by the American Board of Internal Medicine, and in Obesity Medicine by the American Board of Obesity Medicine.

"As healthcare continues to evolve at such a rapid pace, we are excited to add a clinician of Dr. Chiang's caliber to our leadership team," said Giovanni Di Napoli , president of the Gastrointestinal business, which is part of the Medical Surgical Portfolio at Medtronic. "Dr. Chiang's approach to medicine and educating healthcare providers and patients is on the leading edge of healthcare innovation. His forward thinking and desire to personalize medicine for patients and providers will help Medtronic to continue evolving and serving the ever-changing healthcare community."

"I am thrilled to be joining Medtronic at such an innovative time in healthcare and especially in the gastrointestinal space, helping to deliver on what is a promising future for those in need of innovative GI care around the world," said Dr. Chiang. "I look forward to joining a world-renowned team of brilliant engineers and leading clinical experts that produce life-saving devices. I anticipate collaborating with our Medtronic team across the globe to produce solutions that best serve patients and increase quality of care for all."

In addition to serving as Chief Medical Officer for the Medtronic GI business, Dr. Chiang will continue to practice clinically at Jefferson Health. "This is a great step in Dr. Chiang's career as a Jefferson faculty member, and as one of the nation's leading science advocates," said Stephen K. Klasko , M.D., MBA, president of Thomas Jefferson University and CEO of Jefferson Health. "This new role allows him to marry clinical care and device innovation, and to use technology as the foundation for the revolution in putting people first in health care delivery."

A nationally recognized gastroenterologist and advanced endoscopist, Dr. Chiang is passionate about empowering patients with accurate medical information online. He serves on the board of the Association for Bariatric Endoscopy (ABE) and is a committee member for the American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE). He is also founding president of the Association for Healthcare Social Media (AHSM). Dr. Chiang was named Healio Gastroenterology's Disruptive Innovator of the Year in 2018 and was a Philadelphia Inquirer Influencer of Healthcare Rookie of the Year in 2019. This year, Dr. Chiang was a nominee for the GLAAD Media TikTok Advocate of the Year award.

Dr. Chiang completed his undergraduate degree in Biology at Duke University , and he earned his Medical Doctorate from Columbia University before completing his internal medicine residency at New York Presbyterian Hospital ( Columbia University ). He completed his gastroenterology and bariatric endoscopy fellowships at Brigham and Women's Hospital/ Harvard Medical School and advanced endoscopy fellowship at Thomas Jefferson University Hospital. He is also a graduate of the Harvard T.H. Chan School of Public Health where he earned his master's degree in Public Health.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




Sabrina Zimring

Ryan Weispfenning

Public Relations

Investor Relations

+1-720-774-3454

+1-763-505-4626

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/austin-l-chiang-md-mph-joins-medtronic-as-chief-medical-officer-for-gastrointestinal-business-301405157.html

SOURCE Medtronic plc

News Provided by Canada Newswire via QuoteMedia

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion .

"We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper , chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world."

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, it has received TSXV approval, and has closed its acquisition of a 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Strengthens Board of Directors

Leveljump Healthcare Strengthens Board of Directors

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.

Gary Prihar - Director

Keep reading... Show less
ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, is pleased to announce the signing of a Memorandum of Understanding ("MOU") with Infinovo Medical Co. Ltd for a global supply agreement of their P3 Continuous Glucose Monitor (CGM) for use by ALRT in the animal health sector.

Under the terms of the MOU, ALR Technologies and Infinovo will collaborate to integrate Infinovo's P3 CGM with ALRT's proprietary GluCurve platform. The Company expects to begin testing the GluCurve Pet CGM in veterinary clinics in late December 2021 or early January 2022. The testing is scheduled to complete by the end of February 2022.

Keep reading... Show less

Medtronic Hugo robotic-assisted surgery system receives Health Canada licence, further enabling access to robotic-assisted surgery in Canada

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery (RAS) system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1

Keep reading... Show less

APMA Grants Seal of Approval for JUBLIA® Topical Solution, 10%

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

Keep reading... Show less

Top News

Related News